Community

Our community narratives are driven by numbers and valuation.

Value any stock for free in seconds

Get alerts and valuation updates

Participate in discussions

Weekly Picks

RenovoRx

Stock_Research_Today

Community Contributor

Revolutionizing Cancer Treatment

A Precision Approach to Hard-to-Treat Cancers RenovoRx, Inc. (Nasdaq: RNXT), based in Mountain View, California, is a clinical-stage biopharma company taking a new approach to cancer treatment.

View narrative

US$4.20

75.5% undervalued

371.30%

Revenue growth p.a.

15 days ago

Apple

Investingwilly

Community Contributor

Apple: A Dying Star with an Overpriced Valuation

Intro Apple Inc. (AAPL) has long been one of the most beloved stocks in the market, celebrated for its sleek products and loyal customer base.

View narrative

US$177.34

20.1% overvalued

14.68%

Revenue growth p.a.

Updated

Avino Silver & Gold Mines

Agricola

Community Contributor

Avino a case for USD$20 per share within 5 years (assuming $3,500 gold, $100 silver and $4 copper).

Full disclosure. I am a shareholder at the time of writing this.

View narrative

CA$26.79

87.5% undervalued

78.01%

Revenue growth p.a.

15 days ago

RENK Group

Chris1

Community Contributor

Riding the Defense Boom RENK Sees Revenue Climb at 15% CAGR by FY 2029

In a renewed political landscape where a Trump administration adopts a more interventionist stance toward Ukraine, the United States sharply increases its military aid—providing advanced tank transmissions, power packs, and suspension systems. This pivot alleviates initial concerns among European allies, but it simultaneously reinforces the imperative for Europe to shore up its own defense capabilities.

View narrative

€69.87

24.5% undervalued

15.00%

Revenue growth p.a.

16 days ago

Apple

Investingwilly

Community Contributor

Apple: A Dying Star with an Overpriced Valuation

Intro Apple Inc. (AAPL) has long been one of the most beloved stocks in the market, celebrated for its sleek products and loyal customer base.

View narrative

US$177.34

20.1% overvalued

14.68%

Revenue growth p.a.

Updated

lululemon athletica

mschoen25

Community Contributor

Bullish case for Lululemon Athletica (LULU)

Lululemon (LULU) appears to be undervalued based on current analysis. The stock is trading around $281.35, with analysts predicting a consensus price target of $354.94, indicating about a 26% upside potential.

View narrative

US$225.76

37.6% overvalued

10.00%

Revenue growth p.a.

1 day ago

Phillips 66

mschoen25

Community Contributor

room for higher margins

Phillips 66 (PSX) is often considered undervalued for several reasons. Investment analysis typically looks at various factors to determine if a company's stock might be undervalued and whether it has the potential to achieve higher profit margins.

View narrative

US$352.53

64.4% undervalued

13.90%

Revenue growth p.a.

1 day ago

Balfour Beatty

PittTheYounger

Community Contributor

Balfour Beatty to profit from govt's drive for growth

Update as of 13 May: Amidst the tariff chaos and thus increased uncertainty about underlying growth trends, and after Balfour's recent quarterly report, I lowered exp. revenue growth to 12 per cent p.a., increased profit margins just a notch to 3.5 per cent and reduced the discount rate slightly to 9 per cent, still resulting in a fair value close to 600p.

View narrative

UK£5.99

17.7% undervalued

12.00%

Revenue growth p.a.

1 day ago

Global Uranium

Gotbahn

Community Contributor

Vision of a Global Uranium Upsurge with a Price Target of €0.50

Based on the information available, setting a price target of €0.50 for Global Uranium Corp. (DB:Q3J) appears optimistic.

View narrative

€0.50

76.0% undervalued

Revenue growth p.a.

1 day ago

Jumbo Interactive

Robbo

Community Contributor

Undervalued lottery company with strong fundamentals

Jumbo Interactive presents a compelling investment opportunity, with several key metrics indicating that the current share price may be undervalued. Notably, it boasts a strong Joel Greenblatt score of 34 and an attractive dividend yield of 5.4%.

View narrative

AU$15.00

33.3% undervalued

24.34%

Revenue growth p.a.

2 days ago

I-Tech

Mandelman

Community Contributor

I-Tech's Selektope Expansion Will Drive 28% Revenue Increase in 5 Years

Q1 2025 Update Updates to the model and supporting figures below Solid report, above expectation on all lines. Good cashflows, removing doubts/concerns about this topic.

View narrative

SEK 146.82

32.0% undervalued

27.50%

Revenue growth p.a.

4 days ago

EQL Pharma

Mandelman

Community Contributor

EQL Pharma's management aiming for 30% Revenue Growth in 5 Years

2025 Q1 update Strong revenue growth yoy 45% exceding expectations. Strong EPS of 178%, however easy comps should be noted.

View narrative

SEK 86.37

4.5% undervalued

30.00%

Revenue growth p.a.

4 days ago

Sleep Cycle

Mandelman

Community Contributor

Sleep Cycle's Revenue Set to Rise 10% with Strong Revenue Model

Update Q1 2025 (updated 250510) The latest user‐growth data suggest headwinds for top-line revenue, but management’s active repricing initiatives should help offset this. By combining modest user gains with targeted price increases, the company can still drive overall revenue growth.

View narrative

SEK 51.80

40.3% undervalued

10.00%

Revenue growth p.a.

4 days ago

Community

Weekly Picks

Revolutionizing Cancer Treatment

Apple: A Dying Star with an Overpriced Valuation

Avino a case for USD$20 per share within 5 years (assuming $3,500 gold, $100 silver and $4 copper).

Riding the Defense Boom RENK Sees Revenue Climb at 15% CAGR by FY 2029

Apple: A Dying Star with an Overpriced Valuation

Bullish case for Lululemon Athletica (LULU)

room for higher margins

Balfour Beatty to profit from govt's drive for growth

Vision of a Global Uranium Upsurge with a Price Target of €0.50

Undervalued lottery company with strong fundamentals

I-Tech's Selektope Expansion Will Drive 28% Revenue Increase in 5 Years

EQL Pharma's management aiming for 30% Revenue Growth in 5 Years

Sleep Cycle's Revenue Set to Rise 10% with Strong Revenue Model

Value any company in seconds

Popular companies

Community

Weekly Picks

Revolutionizing Cancer Treatment

Apple: A Dying Star with an Overpriced Valuation

Avino a case for USD$20 per share within 5 years (assuming $3,500 gold, $100 silver and $4 copper).

Riding the Defense Boom RENK Sees Revenue Climb at 15% CAGR by FY 2029

Community Investing Ideas

Apple: A Dying Star with an Overpriced Valuation

Bullish case for Lululemon Athletica (LULU)

room for higher margins

Balfour Beatty to profit from govt's drive for growth

Vision of a Global Uranium Upsurge with a Price Target of €0.50

Undervalued lottery company with strong fundamentals

I-Tech's Selektope Expansion Will Drive 28% Revenue Increase in 5 Years

EQL Pharma's management aiming for 30% Revenue Growth in 5 Years

Sleep Cycle's Revenue Set to Rise 10% with Strong Revenue Model

Value any company in seconds

Popular companies